Janssen Global Services, LLC announced that it has submitted an approval request to the U.S. Food and Drug Administration (FDA) for OPSUMIT (macitentan) for treating adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4)
AstraZeneca announced that it has completed the divestment agreement of its established hypertension medicines with Atnahs Pharma UK Limited.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 2845
Published Date: Jul 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing cases of hypertension around the world and the growing prevalence of insomnia across the globe are the major factors driving the growth of the market.
The market size of Hypertension Drugs is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.
The major players in the market are Atnahs Pharma UK Limited, Sanofi US Services Inc., Pfizer Laboratories Div Pfizer Inc, Merck & Co., Inc., Abbott Laboratories, Daiichi Sankyo Company, Limited, and others.
The diuretics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.